Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A method of inhibiting the growth of cancer cells comprising the step of contacting at least one target cell with an effective amount of a peptide hormone derived from the atrial natriuretic peptide prohormone.
2. (Original) The method of claim 1 where the peptide hormone derived from the atrial natriuretic peptide prohormone is selected from the group consisting of atrial natriuretic peptide, long acting natriuretic peptide, vessel dilator, and kiliuretic peptide.
3. (Original) The method of claim 1 wherein the target cell is either an adenocarcinoma, small cell or squamous cell carcinoma
4. (Currently Amended) The method of claim 1 wherein the effective amount of peptide hormone is administered to at least one target cell *in vivo.*
5. (Original) A method of inhibiting the growth of cancer cells comprising the step of co-administering, to at least one target cell, an effective amount of a combination of peptide hormones derived from the atrial natriuretic peptide prohormone.
6. (Original) The method of claim 5 where the combination of peptide hormones derived from the atrial natriuretic peptide prohormone is selected from the group consisting of atrial natriuretic peptide, long acting natriuretic peptide, vessel dilator, and kiliuretic peptide.
7. (Original) The method of claim 5 wherein the target cell is an adenocarcinoma, small cell or squamous cell carcinoma.
8. (Currently Amended) The method of claim 5 wherein the effective amount of the combination of peptide hormones is administered to at least one target cell *in vivo.*
9. (Currently Amended) A method of inhibiting the growth of cancer cells comprising the step of contacting at least one target cell with an effective amount of a peptide hormone derived from the atrial natriuretic peptide prohormone, wherein the peptide hormone derived from the atrial natriuretic peptide prohormone is selected from the group consisting of atrial natriuretic peptide, long acting natriuretic peptide, vessel dilator, and kiliuretic peptide, where the target cell is ~~an~~ chosen from the group consisting of adenocarcinoma, small cell and squamos cell carcinoma, and the effective amount of peptide hormone is administered *in vivo.*
10. (Currently Amended) A method of inhibiting the growth of cancer cells comprising the step of co-administering, to at least one target cell, an effective amount of a combination of peptide hormones derived from the atrial natriuretic peptide prohormone, wherein the combination of peptide hormones derived from

the atrial natriuretic peptide prohormone is selected from the group consisting of atrial natriuretic peptide, long acting natriuretic peptide, vessel dilator, and kiliuretic peptide, where the target cell is chosen from the group consisting of ~~an~~ adenocarcinoma, small cell and squamos cell carcinoma, and the effective amount of the combination of peptide hormones is administered *in vivo*.